Evidence map›Paper›PMID 30740341›Full record

ArticleChonnam medical journal2019

Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis.

Hyung Ki Jeong, Ki Hong Lee, Hyung Wook Park, Nam Sik Yoon, Min Chul Kim, Nuri Lee, Ji Sung Kim, Youngkeun Ahn, Myung Ho Jeong, Jong Chun Park and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chonnam medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hyung Ki JeongDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Ki Hong LeeDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Hyung Wook ParkDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Nam Sik YoonDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Min Chul KimDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Nuri LeeDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Ji Sung KimDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Youngkeun AhnDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Myung Ho JeongDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Jong Chun ParkDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
Jeong Gwan ChoDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation (AF). However, there has been concern for the risk of major bleeding, especially in Asian patients. We investigated the efficacy and safety of rivaroxaban compared to warfarin in Korean real world practice. A total of 2,208 consecutive non-valvular AF patients were divided into the Warfarin group (n=990) and the Rivaroxaban group (n=1218). Propensity matched 1-year clinical outcomes were compared (Warfarin, n=804; Rivaroxaban, n=804). The efficacy outcome was defined as stroke/systemic embolism (SE). The safety outcome was major bleeding. The primary net clinical benefit (NCB) was defined as the composite of stroke/SE, major bleeding, and all-cause mortality. Secondary, NCB was defined as the composite of stroke, SE, and major bleeding. Rivaroxaban had the similar efficacy in terms of thromboembolic event prevention [hazard ratio (HR) 0.69, 95% confidence interval (CI) 0.37-1.32, p=0.266] compared to warfarin. Rivaroxaban significantly lowered the risk of major bleeding [HR 0.41, 95% CI 0.22-0.76, p=0.004]. Primary NCB was significantly low in the rivaroxaban group [HR 0.54, 95% CI 0.36-0.81, p=0.003]. Secondary NCB was also low in the rivaroxaban group [HR 0.62, 95% CI 0.40-0.99, p=0.041]. Both rivaroxaban 15 mg and 20 mg groups had similar efficacy and significantly lower risks of major bleeding as well as primary and secondary NCB compared to the warfarin group. In patients with non-valvular AF, rivaroxaban had a similar efficacy to warfarin in Korean real world practice. However, rivaroxaban had better safety and net clinical outcomes compared to warfarin.

Indexed as

Atrial FibrillationHemorrhageRivaroxabanThromboembolismWarfarin

Identifiers

PMID30740341
PMCPMC6351319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.